Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep;63(3):634–642. doi: 10.1016/j.jhep.2015.04.020

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 European Association for the Study of the Liver. Elsevier B.V. All rights reserved.

This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.

PMC Copyright notice

Fig. 2 — UCL-LDD improves cardiovascular function in ALF. UCL-LDD delayed vasoplegia/high output cardiac failure and reduced severity of cardiovascular failure during the first 8 h of treatment i.e. 2–10 h after ALF (blue shading) in the APAP-UCL-LDD group (solid black line) compared to APAP-CD Group (broken black line) [Control-CD Group (grey line)]. (ALF, time INR exceeded 3; MAP, mean arterial pressure; HR, heart rate; SVRI, systemic vascular resistance index; CI, cardiac index; SVI, stroke volume index; LVSWI, left ventricular stroke work index; RVSWI, right ventricular stroke work index; Voluven, colloid therapy; ^∗, significant (p <0.0500) difference between APAP-UCL-LDD and APAP-CD).